Impact of reporting delay and reporting error on cancer incidence rates and trends
- PMID: 12381706
- DOI: 10.1093/jnci/94.20.1537
Impact of reporting delay and reporting error on cancer incidence rates and trends
Abstract
Background: Cancer incidence rates and trends are a measure of the cancer burden in the general population. We studied the impact of reporting delay and reporting error on incidence rates and trends for cancers of the female breast, colorectal, lung/bronchus, prostate, and melanoma.
Methods: Based on statistical models, we obtained reporting-adjusted (i.e., adjusted for both reporting delay and reporting error) case counts for each diagnosis year beginning in 1981 using reporting information for patients diagnosed with cancer in 1981-1998 from nine cancer registries that participate in the Surveillance, Epidemiology, and End Results (SEER) program. Joinpoint linear regression was used for trend analysis. All statistical tests are two-sided.
Results: Initial incidence case counts (i.e., after the standard 2-year delay) accounted for only 88%-97% of the estimated final counts; it would take 4-17 years for 99% or more of the cancer cases to be reported. The percent change between reporting-adjusted and unadjusted cancer incidence rates for the 1998 diagnosis year ranged from 3% for colorectal cancers to 14% for melanoma in whites and for prostate cancer in black males. Reporting-adjusted current incidence trends for breast cancer and lung/bronchus cancer in white females showed statistically significant increases (estimated annual percent change [EAPC] = 0.6%, 95% confidence interval [CI] = 0.1% to 1.2%) and 1.2%, 95% CI = 0.7% to 1.6%, respectively), whereas trends for these cancers using unadjusted incidence rates were not statistically significantly different from zero (EAPC = 0.4%, 95% CI = -0.1% to 0.9% and 0.5%, 95% CI = -0.1% to 1.1%, respectively). Reporting-adjusted melanoma incidence rates for white males showed a statistically significant increase since 1981 (EAPC = 4.1%, 95% CI = 3.8% to 4.4%) in contrast to the unadjusted incidence rate, which was most consistent with a flat or downward trend (EAPC = -4.2%, 95% CI = -11.1% to 3.3%) after 1996.
Conclusions: Reporting-adjusted cancer incidence rates are valuable in precisely determining current cancer incidence rates and trends and in monitoring the timeliness of data collection. Ignoring reporting delay and reporting error may produce downwardly biased cancer incidence trends, particularly in the most recent diagnosis years.
Similar articles
-
Patterns in cancer incidence among American Indians/Alaska Natives, United States, 1992-1999.Public Health Rep. 2004 Jul-Aug;119(4):443-51. doi: 10.1016/j.phr.2004.05.009. Public Health Rep. 2004. PMID: 15219802 Free PMC article.
-
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study.Cancer Causes Control. 2009 May;20(4):417-35. doi: 10.1007/s10552-008-9256-0. Epub 2008 Nov 12. Cancer Causes Control. 2009. PMID: 19002764 Free PMC article.
-
Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001.J Natl Cancer Inst. 2008 Jul 16;100(14):1003-12. doi: 10.1093/jnci/djn207. Epub 2008 Jul 8. J Natl Cancer Inst. 2008. PMID: 18612132 Free PMC article.
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
-
Differences in cancer incidence, mortality, and survival between African Americans and whites.Environ Health Perspect. 1995 Nov;103 Suppl 8(Suppl 8):275-81. doi: 10.1289/ehp.95103s8275. Environ Health Perspect. 1995. PMID: 8741798 Free PMC article. Review.
Cited by
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.Neuro Oncol. 2024 Oct 6;26(Supplement_6):vi1-vi85. doi: 10.1093/neuonc/noae145. Neuro Oncol. 2024. PMID: 39371035
-
Incidence trends of gastric cancer in the United States over 2000-2020: A population-based analysis.PLoS One. 2024 Sep 25;19(9):e0310040. doi: 10.1371/journal.pone.0310040. eCollection 2024. PLoS One. 2024. PMID: 39321169 Free PMC article.
-
Immunotherapy Improves the Survival of Stage 4 Non-Small Cell Lung Cancer Patients at the US Population Level: The Real-World Evidence.Clin Respir J. 2024 Sep;18(9):e70000. doi: 10.1111/crj.70000. Clin Respir J. 2024. PMID: 39275901 Free PMC article.
-
Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020.Sci Rep. 2024 Sep 3;14(1):20500. doi: 10.1038/s41598-024-69975-3. Sci Rep. 2024. PMID: 39227605 Free PMC article.
-
Lung cancer incidence, 2019-2020, United States: The potential impact of the COVID-19 pandemic.Ann Epidemiol. 2024 Oct;98:44-50. doi: 10.1016/j.annepidem.2024.08.005. Epub 2024 Aug 26. Ann Epidemiol. 2024. PMID: 39197807 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical

